leuprolide acetate depot 22.5 mg — Highmark

Initial criteria

• Diagnosis of advanced prostate cancer (ICD-10: C61)

Reauthorization criteria

• Prescriber attests that the member has experienced a positive clinical response to therapy
• Member requires continued therapy with the requested product

Approval duration

12 months